In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can ...

Personalized therapies for diabetes, while showing promise in international studies, is met with healthy skepticism from ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...